The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for GreenLight Biosciences Holdings (GRNA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.05, or 4.35%, to $1.20. The GreenLight Biosciences Holdings has recorded 7,024 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $1.15 and fluctuated between $1.1701 as its day high and $1.0900 as its day low. The current market capitalization of GreenLight Biosciences Holdings is $165.20M. A total of 0.21 million shares were traded on the day, compared to an average of 359.84K shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, GRNA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 18 BUYs and 0 SELLs from insiders. Insiders purchased 69,250,020 shares during that period but sold 0.
In the most recent transaction, Morningside Venture Investment bought 3,061,224 shares of GRNA for 3.92 per share on Aug 11. After the transaction, the 10% Owner now owns 15,919,155 company shares. In a previous transaction on Aug 11, Builders Vision, LLC bought 6,505,102 shares at 3.92 per share. GRNA shares that 10% Owner owns now total 22,348,123.
Among the insiders who bought shares, Walker Matthew Allen acquired of 6,377,551 shares on Aug 11 at a per-share price of $3.92. This resulted in the Director holding 22,220,572 shares of GRNA after the transaction. In another insider transaction, Walker Matthew Allen bought 63,775 shares at $3.92 per share on Aug 11. Company shares held by the Director now total 63,775.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for GRNA in the last 3 months, the mean price target is $4.75 with high estimates of $5.50 and low estimates of $4.00. In terms of 52-week highs and lows, GRNA has a high of $15.80 and a low of $1.00.
As of this writing, GRNA has an earnings estimate of -$0.28 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$0.28 per share and a lower estimate of -$0.28.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 2 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GRNA is Buy with a score of 5.00. A total of 2 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.